VANCOUVER, Washington — September 16, 2025 — Leads & Copy — CytoDyn Inc. (OTCQB: CYDY) will present a poster and deliver an oral presentation on leronlimab at the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, scheduled for September 24-27, 2025, in Montreal, Canada.
Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will discuss the effects of leronlimab on metastatic triple-negative breast cancer.
According to Dr. Pestell, the findings suggest leronlimab may convert ‘cold’ tumors into ‘hot’ tumors, potentially improving their responsiveness to checkpoint inhibitors in metastatic triple-negative breast cancer. He added the research will help clarify leronlimab’s mechanism of action for solid tumors with limited treatment options.
The poster presentation is scheduled for September 26, 2025, from 6:30 p.m. – 8:30 p.m. EDT, while the podium presentation is on September 27, 2025, from 10:25 a.m. – 10:40 a.m. EDT.
Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn.
Corporate Contact: ir@cytodyn.com
Media Contacts: Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D., CytoDyn@russopartnersllc.com
Source: CytoDyn Inc.
